Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass

Shigeki Tabata, Syohjiro Yamaguchi, Hiroshi Nagamine, Shigeyuki Tomita, Sadahiko Arai, Hirofumi Takemura, Go Watanabe

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: Temporary pharmacologic inhibition of platelet function during and after cardiopulmonary bypass (CPB) (platelet anesthesia) is an attractive strategy for preserving platelets during CPB. We examined the efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist. Methods: The study was carried out in six mongrel dogs that received an intravenous bolus of 0.1 mg/kg of FK633 at the time of administration of heparin (group F), and six control dogs (group C). All animals underwent 60 min of normothermic CPB followed by a 2-h observation period. Blood samples for platelet count, platelet aggregation to adenosine diphosphate and parameters concerning the coagulation system were obtained at eight time points. Hemodynamics, bleeding time, and postoperative blood loss were assessed serially. Scanning electron micrograph of the oxygenator's membrane was investigated. Results: FK633 significantly protected platelet number (group F, 59±10% versus group C, 38±15% of the pre-CPB value; P

Original languageEnglish
Pages (from-to)289-293
Number of pages5
JournalEuropean Journal of Cardio-thoracic Surgery
Volume26
Issue number2
DOIs
Publication statusPublished - Aug 2004
Externally publishedYes

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Aggregation Inhibitors
Cardiopulmonary Bypass
Blood Platelets
Platelet Count
Dogs
Membrane Oxygenators
Postoperative Hemorrhage
Bleeding Time
Platelet Aggregation
Adenosine Diphosphate
Heparin
Anesthesia
Hemodynamics
Observation
Electrons
Control Groups
((4-(4-amidinophenoxy)butanoyl)aspartyl)valine

Keywords

  • Cardiopulmonary bypass
  • Glycoprotein IIb/IIIa antagonist
  • Platelet
  • Platelet anesthesia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass. / Tabata, Shigeki; Yamaguchi, Syohjiro; Nagamine, Hiroshi; Tomita, Shigeyuki; Arai, Sadahiko; Takemura, Hirofumi; Watanabe, Go.

In: European Journal of Cardio-thoracic Surgery, Vol. 26, No. 2, 08.2004, p. 289-293.

Research output: Contribution to journalArticle

Tabata, Shigeki ; Yamaguchi, Syohjiro ; Nagamine, Hiroshi ; Tomita, Shigeyuki ; Arai, Sadahiko ; Takemura, Hirofumi ; Watanabe, Go. / Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass. In: European Journal of Cardio-thoracic Surgery. 2004 ; Vol. 26, No. 2. pp. 289-293.
@article{89224215a71e4593a2a981a81ac45974,
title = "Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass",
abstract = "Objective: Temporary pharmacologic inhibition of platelet function during and after cardiopulmonary bypass (CPB) (platelet anesthesia) is an attractive strategy for preserving platelets during CPB. We examined the efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist. Methods: The study was carried out in six mongrel dogs that received an intravenous bolus of 0.1 mg/kg of FK633 at the time of administration of heparin (group F), and six control dogs (group C). All animals underwent 60 min of normothermic CPB followed by a 2-h observation period. Blood samples for platelet count, platelet aggregation to adenosine diphosphate and parameters concerning the coagulation system were obtained at eight time points. Hemodynamics, bleeding time, and postoperative blood loss were assessed serially. Scanning electron micrograph of the oxygenator's membrane was investigated. Results: FK633 significantly protected platelet number (group F, 59±10{\%} versus group C, 38±15{\%} of the pre-CPB value; P",
keywords = "Cardiopulmonary bypass, Glycoprotein IIb/IIIa antagonist, Platelet, Platelet anesthesia",
author = "Shigeki Tabata and Syohjiro Yamaguchi and Hiroshi Nagamine and Shigeyuki Tomita and Sadahiko Arai and Hirofumi Takemura and Go Watanabe",
year = "2004",
month = "8",
doi = "10.1016/j.ejcts.2004.03.036",
language = "English",
volume = "26",
pages = "289--293",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass

AU - Tabata, Shigeki

AU - Yamaguchi, Syohjiro

AU - Nagamine, Hiroshi

AU - Tomita, Shigeyuki

AU - Arai, Sadahiko

AU - Takemura, Hirofumi

AU - Watanabe, Go

PY - 2004/8

Y1 - 2004/8

N2 - Objective: Temporary pharmacologic inhibition of platelet function during and after cardiopulmonary bypass (CPB) (platelet anesthesia) is an attractive strategy for preserving platelets during CPB. We examined the efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist. Methods: The study was carried out in six mongrel dogs that received an intravenous bolus of 0.1 mg/kg of FK633 at the time of administration of heparin (group F), and six control dogs (group C). All animals underwent 60 min of normothermic CPB followed by a 2-h observation period. Blood samples for platelet count, platelet aggregation to adenosine diphosphate and parameters concerning the coagulation system were obtained at eight time points. Hemodynamics, bleeding time, and postoperative blood loss were assessed serially. Scanning electron micrograph of the oxygenator's membrane was investigated. Results: FK633 significantly protected platelet number (group F, 59±10% versus group C, 38±15% of the pre-CPB value; P

AB - Objective: Temporary pharmacologic inhibition of platelet function during and after cardiopulmonary bypass (CPB) (platelet anesthesia) is an attractive strategy for preserving platelets during CPB. We examined the efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist. Methods: The study was carried out in six mongrel dogs that received an intravenous bolus of 0.1 mg/kg of FK633 at the time of administration of heparin (group F), and six control dogs (group C). All animals underwent 60 min of normothermic CPB followed by a 2-h observation period. Blood samples for platelet count, platelet aggregation to adenosine diphosphate and parameters concerning the coagulation system were obtained at eight time points. Hemodynamics, bleeding time, and postoperative blood loss were assessed serially. Scanning electron micrograph of the oxygenator's membrane was investigated. Results: FK633 significantly protected platelet number (group F, 59±10% versus group C, 38±15% of the pre-CPB value; P

KW - Cardiopulmonary bypass

KW - Glycoprotein IIb/IIIa antagonist

KW - Platelet

KW - Platelet anesthesia

UR - http://www.scopus.com/inward/record.url?scp=3543134181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543134181&partnerID=8YFLogxK

U2 - 10.1016/j.ejcts.2004.03.036

DO - 10.1016/j.ejcts.2004.03.036

M3 - Article

C2 - 15296885

AN - SCOPUS:3543134181

VL - 26

SP - 289

EP - 293

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 2

ER -